As Group Chief Operating Officer, Gowland will further enhance operational performance of all API and Formulated Product manufacturing services, focussing on industry leading product delivery across the Aesica Group.
Aesica has appointed Chris Gowland to the Board
As Group Chief Operating Officer, Gowland will further enhance operational performance of all API and Formulated Product manufacturing services, focussing on industry leading product delivery across the Aesica Group.
Tags
Related posts
- New clinical trial aims to investigate skin patches to spot lung transplant rejection
- CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines
- Researchers introduce new AI tool to help clinicians capture uncertainty in medical images
- New UK report highlights inequalities among people living with breast cancer
- ELRIG UK and SRG collaborate to advance life sciences professionals in drug discovery
